ADAP
Price
$0.74
Change
+$0.02 (+2.74%)
Updated
Sep 20, 6:59 PM EST
42 days until earnings call
ORMP
Price
$2.76
Change
-$0.11 (-3.83%)
Updated
Sep 20, 6:59 PM EST
50 days until earnings call

ADAP vs ORMP ᐉ Comparison: Which is Better to Invest?

Header iconADAP vs ORMP Comparison
Open Charts ADAP vs ORMPBanner chart's image
Adaptimmune Therapeutics
Price$0.74
Change+$0.02 (+2.74%)
Volume$124.49K
CapitalizationN/A
Oramed Pharmaceuticals
Price$2.76
Change-$0.11 (-3.83%)
Volume$102.52K
CapitalizationN/A
View a ticker or compare two or three
ADAP vs ORMP Comparison Chart

Loading...

Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
VS
ADAP vs. ORMP commentary
Sep 21, 2023

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ADAP is a Hold and ORMP is a Hold.

COMPARISON
Comparison
Sep 21, 2023
Stock price -- (ADAP: $0.75 vs. ORMP: $2.76)
Brand notoriety: ADAP and ORMP are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ADAP: 36% vs. ORMP: 84%
Market capitalization -- ADAP: $167.48M vs. ORMP: $116.8M
ADAP [@Biotechnology] is valued at $167.48M. ORMP’s [@Biotechnology] market capitalization is $116.8M. The market cap for tickers in the [@Biotechnology] industry ranges from $424.75B to $0. The average market capitalization across the [@Biotechnology] industry is $2.22B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ADAP’s FA Score shows that 1 FA rating(s) are green whileORMP’s FA Score has 0 green FA rating(s).

  • ADAP’s FA Score: 1 green, 4 red.
  • ORMP’s FA Score: 0 green, 5 red.
According to our system of comparison, ORMP is a better buy in the long-term than ADAP.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ADAP’s TA Score shows that 5 TA indicator(s) are bullish while ORMP’s TA Score has 2 bullish TA indicator(s).

  • ADAP’s TA Score: 5 bullish, 3 bearish.
  • ORMP’s TA Score: 2 bullish, 4 bearish.
According to our system of comparison, ADAP is a better buy in the short-term than ORMP.

Price Growth

ADAP (@Biotechnology) experienced а -7.26% price change this week, while ORMP (@Biotechnology) price change was -4.50% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.61%. For the same industry, the average monthly price growth was +23.29%, and the average quarterly price growth was +30.30%.

Reported Earning Dates

ADAP is expected to report earnings on Nov 02, 2023.

ORMP is expected to report earnings on Nov 10, 2023.

Industries' Descriptions

@Biotechnology (-1.61% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for ADAP with price predictions.
OPEN
A.I.dvisor published
a Summary for ORMP with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
ADAP($167M) has a higher market cap than ORMP($117M). ADAP YTD gains are higher at: -48.973 vs. ORMP (-77.057). ORMP has higher annual earnings (EBITDA): -23.87M vs. ADAP (-102.48M). ADAP has more cash in the bank: 205M vs. ORMP (150M). ORMP has less debt than ADAP: ORMP (724K) vs ADAP (26.3M). ADAP has higher revenues than ORMP: ADAP (70.8M) vs ORMP (2.7M).
ADAPORMPADAP / ORMP
Capitalization167M117M143%
EBITDA-102.48M-23.87M429%
Gain YTD-48.973-77.05764%
P/E RatioN/AN/A-
Revenue70.8M2.7M2,619%
Total Cash205M150M137%
Total Debt26.3M724K3,633%
FUNDAMENTALS RATINGS
ADAP vs ORMP: Fundamental Ratings
ADAP
ORMP
OUTLOOK RATING
1..100
372
VALUATION
overvalued / fair valued / undervalued
1..100
27
Undervalued
36
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9792
PRICE GROWTH RATING
1..100
8164
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ADAP's Valuation (27) in the Biotechnology industry is in the same range as ORMP (36) in the Pharmaceuticals Other industry. This means that ADAP’s stock grew similarly to ORMP’s over the last 12 months.

ADAP's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ORMP (100) in the Pharmaceuticals Other industry. This means that ADAP’s stock grew similarly to ORMP’s over the last 12 months.

ORMP's SMR Rating (92) in the Pharmaceuticals Other industry is in the same range as ADAP (97) in the Biotechnology industry. This means that ORMP’s stock grew similarly to ADAP’s over the last 12 months.

ORMP's Price Growth Rating (64) in the Pharmaceuticals Other industry is in the same range as ADAP (81) in the Biotechnology industry. This means that ORMP’s stock grew similarly to ADAP’s over the last 12 months.

ORMP's P/E Growth Rating (100) in the Pharmaceuticals Other industry is in the same range as ADAP (100) in the Biotechnology industry. This means that ORMP’s stock grew similarly to ADAP’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ADAPORMP
RSI
ODDS (%)
Bullish Trend 3 days ago
90%
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 1 day ago
80%
Momentum
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
78%
MACD
ODDS (%)
Bullish Trend 1 day ago
79%
Bearish Trend 1 day ago
79%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
80%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
82%
Advances
ODDS (%)
Bullish Trend 8 days ago
83%
N/A
Declines
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 1 day ago
84%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
87%
Bullish Trend 1 day ago
70%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
N/A
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GGGPX33.17N/A
N/A
Goldman Sachs Large Cap Core P
TGDVX13.49-0.03
-0.22%
TCW Relative Value Large Cap N
TMAPX46.71-0.15
-0.32%
Touchstone Mid Cap A
AMAKX8.93-0.04
-0.45%
American Century Small Cap Dividend R6
MNNYX52.19-0.45
-0.85%
Victory Munder Multi-Cap Y

ADAP and

Correlation & Price change

A.I.dvisor indicates that over the last year, ADAP has been loosely correlated with ADPT. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if ADAP jumps, then ADPT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ADAP
1D Price
Change %
ADAP100%
+2.41%
ADPT - ADAP
44%
Loosely correlated
-4.60%
ORMP - ADAP
36%
Loosely correlated
-3.83%
CYTK - ADAP
36%
Loosely correlated
-2.92%
NTLA - ADAP
32%
Poorly correlated
-1.11%
ABUS - ADAP
32%
Poorly correlated
+1.01%
More

ORMP and

Correlation & Price change

A.I.dvisor indicates that over the last year, ORMP has been loosely correlated with SRNEQ. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if ORMP jumps, then SRNEQ could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ORMP
1D Price
Change %
ORMP100%
-3.83%
SRNEQ - ORMP
51%
Loosely correlated
-1.15%
KRYS - ORMP
48%
Loosely correlated
-3.55%
VXRT - ORMP
48%
Loosely correlated
+4.51%
AGEN - ORMP
46%
Loosely correlated
-3.23%
MORF - ORMP
46%
Loosely correlated
-3.24%
More